Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy
Copyright © 2021 by the American Society of Nephrology..
BACKGROUND: The activation of NAD+-dependent deacetylase, Sirt1, by the administration of nicotinamide mononucleotide (NMN) ameliorates various aging-related diseases.
METHODS: Diabetic db/db mice were treated with NMN transiently for 2 weeks and observed for effects on diabetic nephropathy (DN).
RESULTS: At 14 weeks after the treatment period, NMN attenuated the increases in urinary albumin excretion in db/db mice without ameliorating hemoglobin A1c levels. Short-term NMN treatment mitigated mesangium expansion and foot process effacement, while ameliorating decreased Sirt1 expression and increased claudin-1 expression in the kidneys of db/db mice. This treatment also improved the decrease in the expression of H3K9me2 and DNMT1. Short-term NMN treatment also increased kidney concentrations of NAD+ and the expression of Sirt1 and nicotinamide phosphoribosyltransferase (Nampt), and it maintained nicotinamide mononucleotide adenyltransferase1 (Nmnat1) expression in the kidneys. In addition, survival rates improved after NMN treatment.
CONCLUSIONS: Short-term NMN treatment in early-stage DN has remote renal protective effects through the upregulation of Sirt1 and activation of the NAD+ salvage pathway, both of which indicate NMN legacy effects on DN.
| Errataetall: |
CommentIn: J Am Soc Nephrol. 2021 Jun 1;32(6):1270-1273. - PMID 33853888 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Journal of the American Society of Nephrology : JASN - 32(2021), 6 vom: 01. Juni, Seite 1355-1370 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yasuda, Itaru [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.10.2021 Date Revised 03.02.2023 published: Print-Electronic CommentIn: J Am Soc Nephrol. 2021 Jun 1;32(6):1270-1273. - PMID 33853888 Citation Status MEDLINE |
|---|
| doi: |
10.1681/ASN.2020081188 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323509320 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323509320 | ||
| 003 | DE-627 | ||
| 005 | 20231225184333.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1681/ASN.2020081188 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1078.xml |
| 035 | |a (DE-627)NLM323509320 | ||
| 035 | |a (NLM)33795425 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yasuda, Itaru |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2021 | ||
| 500 | |a Date Revised 03.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Am Soc Nephrol. 2021 Jun 1;32(6):1270-1273. - PMID 33853888 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 by the American Society of Nephrology. | ||
| 520 | |a BACKGROUND: The activation of NAD+-dependent deacetylase, Sirt1, by the administration of nicotinamide mononucleotide (NMN) ameliorates various aging-related diseases | ||
| 520 | |a METHODS: Diabetic db/db mice were treated with NMN transiently for 2 weeks and observed for effects on diabetic nephropathy (DN) | ||
| 520 | |a RESULTS: At 14 weeks after the treatment period, NMN attenuated the increases in urinary albumin excretion in db/db mice without ameliorating hemoglobin A1c levels. Short-term NMN treatment mitigated mesangium expansion and foot process effacement, while ameliorating decreased Sirt1 expression and increased claudin-1 expression in the kidneys of db/db mice. This treatment also improved the decrease in the expression of H3K9me2 and DNMT1. Short-term NMN treatment also increased kidney concentrations of NAD+ and the expression of Sirt1 and nicotinamide phosphoribosyltransferase (Nampt), and it maintained nicotinamide mononucleotide adenyltransferase1 (Nmnat1) expression in the kidneys. In addition, survival rates improved after NMN treatment | ||
| 520 | |a CONCLUSIONS: Short-term NMN treatment in early-stage DN has remote renal protective effects through the upregulation of Sirt1 and activation of the NAD+ salvage pathway, both of which indicate NMN legacy effects on DN | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a diabetic nephropathy | |
| 650 | 7 | |a Claudin-1 |2 NLM | |
| 650 | 7 | |a Cldn1 protein, mouse |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin A |2 NLM | |
| 650 | 7 | |a Histones |2 NLM | |
| 650 | 7 | |a NAD |2 NLM | |
| 650 | 7 | |a 0U46U6E8UK |2 NLM | |
| 650 | 7 | |a Nicotinamide Mononucleotide |2 NLM | |
| 650 | 7 | |a 1094-61-7 |2 NLM | |
| 650 | 7 | |a DNA (Cytosine-5-)-Methyltransferase 1 |2 NLM | |
| 650 | 7 | |a EC 2.1.1.37 |2 NLM | |
| 650 | 7 | |a Dnmt1 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 2.1.1.37 |2 NLM | |
| 650 | 7 | |a Nicotinamide Phosphoribosyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.4.2.12 |2 NLM | |
| 650 | 7 | |a nicotinamide phosphoribosyltransferase, mouse |2 NLM | |
| 650 | 7 | |a EC 2.4.2.12 |2 NLM | |
| 650 | 7 | |a Nicotinamide-Nucleotide Adenylyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.7.7.1 |2 NLM | |
| 650 | 7 | |a Nmnat1 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 2.7.7.1 |2 NLM | |
| 650 | 7 | |a Sirt1 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 3.5.1.- |2 NLM | |
| 650 | 7 | |a Sirtuin 1 |2 NLM | |
| 650 | 7 | |a EC 3.5.1.- |2 NLM | |
| 700 | 1 | |a Hasegawa, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sakamaki, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Muraoka, Hirokazu |e verfasserin |4 aut | |
| 700 | 1 | |a Kawaguchi, Takahisa |e verfasserin |4 aut | |
| 700 | 1 | |a Kusahana, Ei |e verfasserin |4 aut | |
| 700 | 1 | |a Ono, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Kanda, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tokuyama, Hirobumi |e verfasserin |4 aut | |
| 700 | 1 | |a Wakino, Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Itoh, Hiroshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Society of Nephrology : JASN |d 1990 |g 32(2021), 6 vom: 01. Juni, Seite 1355-1370 |w (DE-627)NLM012606502 |x 1533-3450 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:6 |g day:01 |g month:06 |g pages:1355-1370 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1681/ASN.2020081188 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2021 |e 6 |b 01 |c 06 |h 1355-1370 | ||